MichaelFrederickEganMD

PubMed

• 7 citations
  Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy.
  Robert C. Sergott, Annaswamy Raji, James Kost, Cyrille Sur, Saheeda Jackson, Amy Locco, Arpankumar Patel, Christine Furtek, Britta A. Mattson, Michael F. Egan> ;Journal of Alzheimer's Disease. 2021 Jan 1
• 35 citations
  BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain
  Cyrille Sur, James Kost, David Scott, Katarzyna Adamczuk, Nick C. Fox, Jeffrey L. Cummings, Pierre N. Tariot, Paul S. Aisen, Bruno Vellas, Tiffini Voss, Erin Mahoney, ...> ;Brain. 2020 Dec 1
• 37 citations
  Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
  Alette M. Wessels, Christopher Lines, Robert S. Stern, James Kost, Tiffini Voss, Lyn Harper Mozley, Christine Furtek, Yuki Mukai, Paul S. Aisen, Jeffrey L. Cummings, P...> ;Alzheimer's & Dementia. 2020 Oct 13
• 43 citations
  Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
  Michael F. Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie A. Stone, Christine Furtek, Erin Mahoney, Jeffrey L. Cummings, Pierre N. Tariot, Paul S. Aisen, Bruno Vell...> ;Alzheimer's Research & Therapy. 2019 Aug 7
• 156 citations
  Convergence of placenta biology and genetic risk for schizophrenia.
  Gianluca Ursini, Giovanna Punzi, Qiang Chen, Stefano Marenco, Joshua F. Robinson, Annamaria Porcelli, Emily G. Hamilton, Marina Mitjans, Giancarlo Maddalena, Martin Be...> ;Nature Medicine. 2018 May 28
• 394 citations
  Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
  Michael F. Egan, James Kost, Pierre N. Tariot, Paul S. Aisen, Jeffrey L. Cummings, Bruno Vellas, Cyrille Sur, Yuki Mukai, Tiffini Voss, Christine Furtek, Erin Mahoney,...> ;The New England Journal of Medicine. 2018 May 2
• 35 citations
  Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.
  Tiffini Voss, Jerry Li, Jeffrey L Cummings, Martin R. Farlow, Christopher Assaid, Samar Froman, Heather Leibensperger, Linda Snow-Adami, Kerry Budd McMahon, Michael F....> ;Alzheimer's & Dementia. 2018 Jan 1
• 18 citations
  A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomograph...
  Yi Mo, Julie Stromswold, Kimberly Wilson, Daniel J. Holder, Cyrille Sur, Omar F Laterza, Mary J. Savage, Arie Struyk, Philip Scheltens, Charlotte E. Teunissen, James R...> ;Alzheimer's & Dementia. 2017 Jan 1
• 284 citations
  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
  Matthew E. Kennedy, Andrew Stamford, Xia Chen, Kathleen Cox, Jared N. Cumming, Marissa F. Dockendorf, Michael F. Egan, Larry Ereshefsky, Robert A. Hodgson, Lynn A. Hyd...> ;Science Translational Medicine. 2016 Nov 2
• 4 citations
  Perceptual Category Judgment Deficits are Related to Prefrontal Decision Making Abnormalities in Schizophrenia
  Thomas W. Weickert, Alejandro Terrazas, Llewellyn B. Bigelow, Jose A. Apud, Michael F. Egan, Daniel R. Weinberger> ;Frontiers in Psychiatry. 2014 Jan 6
• 11 citations
  Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson’s disease
  Thomas W. Weickert, Venkata S. Mattay, Saumitra Das, Llewellyn B. Bigelow, Jose A. Apud, Michael F. Egan, Daniel R. Weinberger, Terry E. Goldberg> ;Schizophrenia Research. 2013 Sep 1
• 36 citations
  Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
  Michael F. Egan, Xin Zhao, Regina Gottwald, Lyn Harper-Mozley, Ying Zhang, Duane B. Snavely, Christopher Lines, David Michelson> ;Schizophrenia Research. 2013 May 1
• 20 citations
  Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human
  Eric D. Hostetler, Sandra M. Sanabria-Bohórquez, Wai-Si Eng, Aniket Joshi, Shailendra Patel, Raymond E. Gibson, Stacey O'Malley, Stephen Krause, Christine Ryan, Kerry ...> ;Neuroimage. 2013 Mar 1
• 29 citations
  Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.
  Michael F. Egan, Xin Zhao, Andrew Smith, Matthew D. Troyer, Victor N. Uebele, Valerii Pidkorytov, Kevin Cox, Michael F. Murphy, Duane B. Snavely, Christopher Lines, Da...> ;Human Psychopharmacology. 2013 Mar 1
• Barry Commoner's Place in History
  Michael Egan> ;Science. 2012 Nov 23
• 30 citations
  Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.
  Michael F. Egan, Roy Yaari, Lian Liu, Michael S Ryan, Yahong Peng, Christopher Lines, David Michelson> ;Current Alzheimer Research. 2012 May 1
• 19 citations
  Magnitude of Impact of Executive Functioning and IQ on Episodic Memory in Schizophrenia
  Brandon E. Kopald, Kathryn M. Mirra, Michael F. Egan, Daniel R. Weinberger, Terry E. Goldberg> ;Biological Psychiatry. 2012 Mar 15
• 60 citations
  Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder
  Mady Hornig, Thomas Briese, Julio Licinio, R. F. Khabbaz, Lori L. Altshuler, Steven G. Potkin, Martin Schwemmle, Ulrike Siemetzki, Jim Mintz, Kirsi S. Honkavuori, Hele...> ;Molecular Psychiatry. 2012 Jan 31
• 29 citations
  Relative risk of probabilistic category learning deficits in patients with schizophrenia and their siblings.
  Thomas W. Weickert, Terry E. Goldberg, Michael F. Egan, Jose A. Apud, Martijn Meeter, Catherine E. Myers, Mark A. Gluck, Daniel R. Weinberger> ;Biological Psychiatry. 2010 May 15
• 26 citations
  The Premorbid Adjustment Scale as a Measure of Developmental Compromise in Patients with Schizophrenia and their Healthy Siblings
  D.I. Shapiro, Stefano Marenco, E.H. Spoor, Michael F. Egan, D.R. Weinberger, James M. Gold> ;Schizophrenia Research. 2009 Jul 1
• 188 citations
  A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia
  Stephen J. Huffaker, Jingshan Chen, Kristin K. Nicodemus, Fabio Sambataro, Feng Yang, Venkata S. Mattay, Barbara K. Lipska, Thomas M. Hyde, Jian Song, Dan Rujescu, Ina...> ;Nature Medicine. 2009 May 1
• 62 citations
  Neural correlates of probabilistic category learning in patients with schizophrenia
  Thomas W. Weickert, Terry E. Goldberg, Joseph H. Callicott, Qiang Chen, Jose A. Apud, S. Das, Brad Zoltick, Michael F. Egan, Martijn Meeter, Catherine E. Myers, Mark A...> ;The Journal of Neuroscience. 2009 Jan 28
• 76 citations
  Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function.
  Lucas Kempf, Kristin K. Nicodemus, Bhaskar Kolachana, Radhakrishna Vakkalanka, Beth A. Verchinski, Michael F. Egan, Richard E. Straub, Venkata A. Mattay, Joseph H. Cal...> ;Plos Genetics. 2008 Nov 7
• 80 citations
  Set-Shifting Ability and Schizophrenia : A Marker of Clinical Illness or an Intermediate Phenotype?
  Alan E. Ceaser, Terry E. Goldberg, Michael F. Egan, Robert P. McMahon, Daniel R. Weinberger, James M. Gold> ;Biological Psychiatry. 2008 Nov 1
• 55 citations
  Verbal and visual memory: characterizing the clinical and intermediate phenotype in schizophrenia.
  Shayna L. Skelley, Terry E. Goldberg, Michael F. Egan, Daniel R. Weinberger, James M. Gold> ;Schizophrenia Research. 2008 Oct 1
• Join now to see all